CARE: Rivaroxaban for COVID-19 Outpatients Trial Data
by Gustavo Bernardes de Figueiredo Oliveira
Available on 1 platform
Sign in to view source links and access this dataset
Description
A clinical trial dataset from the CARE study, a multicenter, randomized, open-label, controlled trial registered at clinicaltrials.gov (NCT04757857). The study, authored by Gustavo Bernardes de Figueiredo Oliveira, assessed whether 14 days of rivaroxaban prophylaxis reduced thrombotic events, invasive ventilation, or death in adults with mild or moderate COVID-19 symptoms. Outcomes were centrally adjudicated by an independent clinical events committee.
Use Cases
Evaluate the efficacy of rivaroxaban for preventing venous thromboembolism in COVID-19 outpatients based on the described primary composite endpoint.
Analyze risk factors for COVID-19 complications, such as age over 65 or diabetes, mentioned in the inclusion criteria.
Study the relationship between antithrombotic prophylaxis and the need for invasive mechanical ventilation as described in the trial objectives.
Assess major acute cardiovascular events and mortality within 30 days of randomization as defined by the trial protocol.
Strengths
Data originates from a registered, multicenter randomized controlled trial (NCT04757857), suggesting a structured collection process.
Clinical outcomes were centrally adjudicated by an independent committee blinded to treatment groups, which likely enhances data reliability.
The study design includes specific inclusion criteria (e.g., adults within 7 days of symptom onset with at least one risk factor) and a defined primary composite endpoint.
Limitations
Column-level documentation is absent; field semantics must be inferred after download.
Row count is unknown, which may limit suitability assessment for specific analytical tasks.
Last update date is unknown; freshness unverified.
Provenance
Source
paperswithcode, linked to the clinical trial NCT04757857.
Collection Method
Data collected as part of the COVID Antithrombotic Rivaroxaban Evaluation (CARE) clinical trial.
Geography
Likely Brazil, inferred from the study's subtitle 'Coalition COVID-19 Brazil VIII'.
License is listed as Open Access (green), but specific terms for data reuse should be verified from the original trial registry or publication.